T. Fujioka et al., Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma, ONCOL REP, 8(2), 2001, pp. 249-255
Protein expression levels of E-cadherin and beta -catenin were examined in
39 primary and 10 metastatic ovarian carcinoma to elucidate the role of the
se molecules in the extension of ovarian carcinoma by immunohistochemistry.
Twenty-two of 39 (56%) ovarian carcinomas were preserved type and 17 of 39
(44%) were reduced type of E-cadherin. In contrast, 36 of 39 (92%) ovarian
carcinomas were preserved type and 3 of 39 (8%) were reduced type of beta
-catenin. E-cadherin expression in well-differentiated carcinoma was higher
than that in moderately/poorly-differentiated carcinoma (p<0.05). Interest
ingly, 6 of 10 (60%) peritoneal metastatic lesions resulted in the reduced
expression of E-cadherin compared with primary lesions. In contrast, only 2
of 10 (20%) metastatic lesions showed reduced expression of <beta>-catenin
compared with primary lesions. Mutation of exon 3 of beta -catenin gene wa
s rare (3%, 1/39) in carcinoma. These results suggested that the cell adhes
ion molecule E-cadherin might play an important role in the formation of pe
ritoneal metastasis. In contrast, beta -catenin is not a good indicator of
metastasis in human ovarian carcinoma.